TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:TEVA

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/09	20:53	IH Market News	Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/08	20:00	Business Wire	Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/08	19:30	Business Wire	Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/03	07:30	Business Wire	Teva to Present at the 2024 Bank of America Healthcare Conference	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/02	21:30	Business Wire	Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/30	17:00	Business Wire	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/30	17:00	GlobeNewswire Inc.	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/17	06:43	Business Wire	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/17	06:30	GlobeNewswire Inc.	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/16	21:00	Business Wire	Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/11	21:30	Business Wire	Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/10	05:30	Business Wire	Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/07	02:00	Business Wire	New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/04	21:30	Business Wire	Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/01	21:30	Business Wire	Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:43	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd